Gas Exchange Pulmonary Function Testing Market

Gas Exchange Pulmonary Function Testing Market Size

The global gas exchange pulmonary function testing market was valued at USD 249.3 million in 2024. The market is expected to reach from USD 261 million in 2025 to USD 450.7 million in 2034, growing at a CAGR of 6.3% during the forecast period, according to the latest report published by Global Market Insights Inc. Growing incidence of chronic respiratory ailments, higher uptake of CPET and DLCO testing, and increasing hospital diagnostic facilities are fueling the market growth.

The gas exchange pulmonary function testing market provides innovative diagnostic solutions to payers, providers, life sciences firms, and healthcare technology companies to improve regulatory compliance, patient outcomes, and clinical efficiency. Solutions cover cardiopulmonary exercise testing (CPET) systems, gas diffusion analyzers, spirometry platforms, and combined digital health tools that enable precise diagnosis, disease management, and enhanced quality of care. These are competitive with each other by constantly developing new products, having a strong international presence, strategic partnerships, and major investments in research and development to address changing clinical needs and further penetrate markets.

The market has increased from USD 217.8 million in 2021 and reached USD 238.5 million in 2023. The gas exchange pulmonary function testing market is experiencing steady growth, driven by multiple interrelated factors that reflect both the rising burden of respiratory disease and advancements in diagnostic technologies. The increasing prevalence of chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and interstitial lung diseases has created strong demand for advanced diagnostic tools that enable early detection, precise monitoring, and effective management of patient health. Growing awareness among healthcare providers and patients about the benefits of cardiopulmonary exercise testing (CPET) and gas diffusion capacity (DLCO) testing is further expanding adoption rates, particularly in hospitals, specialized clinics, and diagnostic centers.

Expanding healthcare infrastructure, especially in developing regions, coupled with greater availability of portable and digital testing systems, is enhancing accessibility to high-quality diagnostic solutions. Moreover, continuous innovation in pulmonary testing devices, including the integration of digital health platforms, AI-driven analytics, and user-friendly interfaces, is improving efficiency, compliance, and patient outcomes. Favorable reimbursement policies in developed markets and an increasing focus on preventive care are also supporting the uptake of advanced PFT systems.

Gas exchange pulmonary function testing is a diagnostic method that evaluates how efficiently the lungs transfer oxygen into the blood and remove carbon dioxide. Using techniques like diffusion capacity (DLCO) and cardiopulmonary exercise testing (CPET), it helps assess respiratory health, detect abnormalities, and guide management of chronic pulmonary diseases.

Gas Exchange Pulmonary Function Testing Market Trends

The increasing incidence of respiratory conditions, such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and interstitial lung diseases, is a major growth driver for the market.

• Macro economically, rising urbanization, air pollution, and age factors are also driving higher rates of chronic respiratory diseases worldwide, which in turn is fueling demand for diagnostic technologies among healthcare systems. Governments and health policymakers are focusing on early detection and preventive treatment to minimize long-term healthcare expenditures, thereby pushing healthcare investments towards pulmonary diagnostic infrastructure as well.
  
• From a micro economic view, individual clinics, diagnostic centers, and hospitals are increasingly using advanced PFT devices in order to better manage patient outcomes, streamline treatment protocols, and decrease readmission rates, as well as differentiate themselves in competitive healthcare markets. Increasing numbers of patients with respiratory diseases also fuel revenue growth for diagnostic device manufacturers as healthcare providers look for accurate, efficient, and reliable solutions for managing larger patient volumes.
  
• Technological advancements are amplifying this trend by enabling more precise and versatile testing methods, such as cardiopulmonary exercise testing (CPET), gas diffusion capacity (DLCO) analysis, and integrated spirometry platforms. Innovations in digital health integration, portable and handheld devices, and AI-driven data analytics allow clinicians to monitor lung function more effectively, both in hospitals and home healthcare settings, enhancing early diagnosis and long-term disease management.
  
• Collectively, the interplay of these macro- and micro-economic factors, along with continuous technological innovation, positions the increasing prevalence of respiratory diseases as a critical catalyst for the expansion of the market, driving both adoption and development of advanced pulmonary diagnostic solutions worldwide.
  

Gas Exchange Pulmonary Function Testing Market Analysis

Based on the system type, the market is segmented into portable and stationary. The portable segment has asserted its dominance in the market by securing a significant market share of 82.8% in 2024, driven by rising demand for home-based and point-of-care respiratory monitoring drives growth. The segment is expected to exceed USD 379.6 million by 2034, growing at a CAGR of 6.4% during the forecast period. On the other hand, the stationary segment is expected to grow with a CAGR of 5.3%. The growth of this segment can be attributed to the preference for hospital-based comprehensive diagnostics, fuels stationary device adoption.

• The portable segment is led mainly by the growing need for home and point-of-care respiratory monitoring. The prevalence of chronic respiratory conditions like COPD, asthma, and interstitial lung disease has prompted patients and clinicians to embrace portable devices for regular, easy, and instantaneous lung function tests outside the hospital environment.
  
• Advances in technology, such as lightweight designs, wireless communications, onboard digital health platforms, and easy-to-use interfaces, have further increased the use and precision of portable devices, allowing them to be used for home care and remote monitoring.
  
• The increasing availability of telehealth platforms and AI-enabled analytics also encourages integration of portable PFT devices into modern healthcare workflows, driving widespread adoption globally.
  
• The stationary segment held a revenue of USD 42.9 million in 2024, with projections indicating a steady expansion at 5.3% CAGR from 2025 to 2034. The stationary segment is driven by the need for comprehensive, high-precision diagnostic solutions in hospitals and specialized pulmonary centers. Stationary systems, including body plethysmographs, integrated spirometry workstations, and gas diffusion analyzers, are preferred in hospital settings for their ability to perform multi-parameter testing, including cardiopulmonary exercise testing (CPET) and DLCO measurements, providing detailed insights into complex respiratory conditions.
  
• Continuous technological advancements, including improved software interfaces, digital data integration, and enhanced calibration and safety features, make stationary devices reliable and durable, reinforcing their adoption despite higher costs, and fueling long-term market growth.
  

Based on test method, the gas exchange pulmonary function testing market is bifurcated into gas diffusion tests and cardiopulmonary exercise testing (CPET). The gas diffusion tests segment dominated the market with a revenue share of 61% in 2024 and is expected to reach USD 263.7 million within the forecast period.

• Tests of gas diffusion, which essentially quantify the lung's ability to transfer gases such as oxygen and carbon dioxide (DLCO), are an important diagnostic tool for the detection and treatment of chronic respiratory illnesses like COPD, pulmonary fibrosis, and interstitial lung diseases.
  
• Increasing cases of these diseases around the world have pushed the demand for reliable and timely diagnosis, making gas diffusion testing a method of choice in hospitals, specialty clinics, and diagnostic laboratories. Advances in technology, such as automated DLCO analyzers, spirometry module integration, and digital health platforms for managing data, have enhanced accuracy, workflow, and patient tracking.
  
• Collaborative government policies, enhanced reimbursement for pulmonary diagnostics, and rising clinician and patient awareness about the importance of early intervention fuel adoption.
  
• The cardiopulmonary exercise testing (CPET) segment held a revenue of USD 97.2 million in 2024, with projections indicating a steady expansion at 6.9% CAGR from 2025 to 2034. The rising incidence of chronic respiratory and cardiovascular diseases, along with increasing patient awareness, is fueling demand for CPET as a diagnostic and prognostic tool in clinical and rehabilitation settings. CPET aids in differentiating cardiac from pulmonary causes of dyspnea, evaluating disease progression, and tailoring personalized treatment plans.
  
• Technological advancements, such as portable metabolic carts, wearable sensors, breath-by-breath gas analysis, and integration with digital health platforms, have made CPET more accessible, accurate, and patient-friendly.
  
• Growing adoption in hospitals, specialty clinics, and rehabilitation centers, coupled with favorable reimbursement policies and an emphasis on preventive care, further supports market expansion.
  

Based on application, the gas exchange pulmonary function testing market is classified into chronic obstructive pulmonary disease, asthma, chronic shortness of breath, pulmonary fibrosis, and other applications. The chronic obstructive pulmonary disease segment dominated the market with a revenue share of 47.5% in 2024 and is expected to reach USD 216.7 million within the forecast period.

• Increased patient and doctor awareness of early diagnosis and management of the disease has driven demand for precise pulmonary function tests, such as spirometry, gas diffusion (DLCO), and cardiopulmonary exercise testing (CPET).
  
• Advances in technology of PFT devices, including integrated digital health solutions and AI-driven analytics, enable more accurate monitoring of lung function, facilitating enhanced clinical decision-making and outcomes for patients.
  
• The asthma segment held a revenue of USD 68.1 million in 2024, with projections indicating a steady expansion at 6.8% CAGR from 2025 to 2034. The asthma segment is witnessing significant growth due to the rising incidence of asthma across all age groups, particularly among children and young adults, influenced by environmental pollution, allergens, and urbanization.
  
• Growing patient awareness and proactive disease management practices have led to increased adoption of pulmonary function testing for accurate diagnosis, monitoring, and treatment evaluation. Technological innovations in spirometry, portable PFT devices, and digital health platforms allow real-time monitoring of lung function, enabling personalized treatment and improved patient compliance.
  
• The chronic shortness of breath segment held a revenue of USD 26.7 million in 2024, with projections indicating a steady expansion at 5.5% CAGR from 2025 to 2034. The chronic shortness of breath segment is growing due to the rising prevalence of respiratory, cardiovascular, and metabolic disorders that manifest as dyspnea, increasing the need for comprehensive pulmonary evaluation.
  
• Gas exchange pulmonary function testing, including CPET and DLCO assessments, provides objective insights into functional limitations and aids in differential diagnosis. Technological advancements, such as integrated CPET systems, portable PFT devices, and AI-based data analytics, allow clinicians to perform efficient, accurate, and non-invasive assessments, enhancing patient management.
  

Based on end use, the gas exchange pulmonary function testing market is classified into hospitals & clinics, diagnostic centers, and other end users. The hospitals & clinics segment dominated the market with a revenue share of 62.4% in 2024 and is expected to reach USD 278.3 million within the forecast period.

• The two largest segments account for over 91.7% of the total market value. The hospitals and clinics segment leads the market because of its large infrastructure, large patient flow, and capability to offer complete diagnostic services. Rising incidence of chronic respiratory conditions like COPD, asthma, and pulmonary fibrosis compels hospitals to implement advanced PFT systems, such as CPET, DLCO, and combined spirometry platforms, for precise diagnosis and efficient disease management.
  
• Hospitals are driven to prioritize high-quality, dependable testing devices to enable multidisciplinary treatment and minimize hospital readmission, further driving adoption. Advances in technology, including AI-powered analysis, cloud storage, and mobile devices, enable hospitals to streamline workflows, maximize patient monitoring, and enhance operating efficiency.
  
• The diagnostic centers segment held a revenue of USD 73 million in 2024, with projections indicating a steady expansion at 6.7% CAGR from 2025 to 2034. Diagnostic centers are emerging as a significant growth driver for the gas exchange pulmonary function testing market due to their increasing role in outpatient respiratory care and early disease detection.
  
• Rising awareness of respiratory health among patients and the growing prevalence of chronic lung conditions prompt diagnostic centers to adopt advanced PFT systems, including gas diffusion analyzers, CPET equipment, and spirometry devices.
  

North America Gas Exchange Pulmonary Function Testing Market

The North America market dominated the market with a market share of 40.2% in 2024.

• North America is propelled by its sophisticated healthcare infrastructure, heavy disease burden, and swift uptake of diagnostic technologies. The region's aging population, who are getting more and more afflicted with chronic respiratory diseases like COPD, asthma, and pulmonary fibrosis, is one of the primary drivers of demand for accurate lung function measurements such as gas diffusion and cardiopulmonary exercise testing.
  
• Government programs, respiratory health societies, and hospital chains are encouraging early diagnosis and regular follow-up through clinical awareness and preventive care programs, increasing the patient base. Advances in technology, such as AI-based interpretation software, wireless transmission, and compact spirometers, are revolutionizing the delivery of care. Players like ndd Medical Technologies, COSMED, and Vitalograph are launching intelligent, mobile-app-compatible devices that facilitate remote testing and integration with telehealth.
  
• Supportive reimbursement frameworks, rising healthcare expenditure, and the shift toward outpatient and home-based care are enhancing accessibility to pulmonary diagnostics. Hospitals and clinics remain dominant end-users, but diagnostic centers and home care settings are gaining traction due to the convenience and cost-effectiveness of portable systems. With growing awareness of air pollution and occupational lung diseases, North America continues to solidify its leadership in the market.
  

The U.S. gas exchange pulmonary function testing was valued at USD 84.3 million and USD 87.7 million in 2021 and 2022, respectively. The market size reached USD 94.4 million in 2024, growing from USD 91 million in 2023.

• The U.S. gas exchange pulmonary function testing market is propelled by a high prevalence of chronic respiratory diseases, including COPD, asthma, and interstitial lung disorders, alongside a robust healthcare infrastructure and strong presence of leading diagnostic technology firms. The aging population and lifestyle factors such as smoking, pollution exposure, and sedentary habits contribute to increased demand for precise lung function assessments.
  
• Furthermore, advanced diagnostic capabilities and widespread awareness initiatives driven by government agencies, respiratory health organizations, and hospital networks support early detection and routine monitoring. The market is seeing a shift toward portable and AI-integrated systems, enabling remote testing and telehealth compatibility.
  
• Additionally, favorable reimbursement policies, high healthcare spending, and growing outpatient volumes in physician clinics and diagnostic centers are enhancing accessibility. The integration of digital health platforms and real-time monitoring tools is improving care delivery and patient engagement. With continuous innovation and strong institutional support, the U.S. remains a central hub for growth and adoption in the market.
  

Europe Gas Exchange Pulmonary Function Testing Market

Europe market accounted for USD 66.1 million in 2024 and is anticipated to show lucrative growth over the forecast period.

• Strong public health infrastructure, an aging population, and a rising burden of respiratory diseases support the growth of the European market. Respiratory diseases caused 6.1% of all EU deaths in 2021, at a greater rate than in countries such as Denmark and Malta, as per Eurostat.
  
• Policy support and clinical guidelines from the European Medicines Agency (EMA) and WHO Europe are enhancing diagnostic standards and promoting innovation. EMA guidelines emphasize the importance of gas exchange testing in evaluating therapeutic efficacy for COPD treatments, while WHO reports highlight the need for integrated care and early diagnosis to reduce chronic respiratory disease burden 3. European manufacturers are also ensuring the availability of certified lung function gas mixtures for diffusion testing, with no reported shortages across healthcare facilities
  
• Moreover, the area is blessed with harmonized medical device regulations, preventive care programs, and universal hospital-based screening programs. Portable and AI-based pulmonary function testing systems are increasingly popular in outpatient and home care environments, complemented by EU-wide initiatives to digitalize healthcare and enhance access.
  

Germany dominates the European gas exchange pulmonary function testing market, showcasing strong growth potential.

• The country’s statutory health insurance covers nearly 90% of the population, ensuring broad access to diagnostic services including spirometry, lung volume, and diffusion capacity tests. Chronic respiratory diseases such as COPD and asthma are major public health concerns, with Germany contributing significantly to the EU’s respiratory disease burden.
  
• The WHO and European Respiratory Society report highlight underdiagnosis and poor management of chronic respiratory diseases across Europe, but Germany stands out for its structured hospital reforms and emphasis on outpatient care. The country is actively transitioning inpatient procedures to day treatments, improving diagnostic throughput, and reducing system strain.
  
• Germany benefits from EU-wide medical device regulations and WHO-endorsed standards, ensuring the availability and safety of pulmonary testing equipment. The European Medicines Agency plays a key role in certifying high-risk diagnostic devices, including those used in gas exchange testing. With strong regulatory alignment, high disease prevalence, and ongoing investments in healthcare modernization, Germany continues to lead the European market in pulmonary function diagnostics.
  

Asia Pacific Gas Exchange Pulmonary Function Testing Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 7.5% during the analysis timeframe.

• The Asia Pacific is emerging as a dynamic market for gas exchange pulmonary function testing, fueled by the expanding burden of respiratory disease, urbanization, and aging populations. As per the Asia Pacific Observatory on Health Systems and Policies, nations like China, India, Japan, and Australia are experiencing rising demand for diagnostic services given high prevalence rates of COPD, asthma, and occupational lung diseases.
  
• Additionally, primary health care systems are also being built up in South East Asia, and the Pacific, with regional priorities such as the integration of telemedicine, quality, and regulation of private diagnostic services. WHO reports highlight the necessity of enhanced access to pulmonary diagnostics and stress the need for gas exchange testing in the management of non-communicable diseases.
  
• The WHO Global Atlas of Medical Devices confirms rising availability of pulmonary testing devices throughout Asia Pacific, with higher utilization of spirometry, diffusion capacity testing, and FeNO monitoring in hospitals and outpatient clinics. With continuing investment in health system upgrade and digital healthcare, Asia Pacific is expected to experience robust growth in gas exchange pulmonary function testing.
  

China gas exchange pulmonary function testing market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• According to the WHO, nearly 100 million Chinese adults live with COPD, accounting for about 25% of global cases. Despite this, only 10% had ever received a pulmonary function test as of 2015, highlighting a major diagnostic gap that the government has actively worked to close.
  
• Additionally, the Chinese government has launched nationwide initiatives to improve early diagnosis and pulmonary care, including the distribution of 30,000 portable spirometry devices and training of over 140,000 primary healthcare workers between 2020-2023. These efforts are part of China’s Medium-to-Long Term Plan for Chronic Disease Prevention and align with WHO’s global action plan.
  
• Furthermore, China’s medical device ecosystem is also expanding, supported by WHO’s Global Atlas of Medical Devices, which confirms the country’s growing capacity in health technology regulation, device availability, and biomedical engineering resources. With increasing access to pulmonary testing equipment and rising awareness of respiratory health, China is positioned as a key growth engine in the Asia Pacific market.
  

Latin American Gas Exchange Pulmonary Function Testing Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• Brazil leads the Latin American gas exchange pulmonary function testing market, exhibiting remarkable growth driven by its expansive healthcare infrastructure, rising respiratory disease burden, and increasing adoption of diagnostic technologies. Brazil is the largest healthcare market in Latin America, spending 9.7% of its GDP on healthcare, with over 7,300 hospitals and a mix of public and private systems serving more than 200 million people.
  
• The Brazilian Health Regulatory Agency (ANVISA) plays a central role in regulating medical devices and diagnostics, ensuring safety and efficacy standards aligned with international norms. Brazil is also part of the Medical Devices Single Audit Program (MDSAP), which facilitates faster approval of imported technologies. According to the WHO’s Global Atlas of Medical Devices, Brazil has made significant progress in expanding access to diagnostic equipment, including spirometry and gas exchange testing systems.
  
• Public and private sector investments in digital health and medical technology are accelerating market growth. The Ministry of Health has launched initiatives to digitize primary care and expand telemedicine, particularly in underserved regions. With strong regulatory oversight, growing awareness of respiratory health, and increasing availability of diagnostic tools, Brazil continues to dominate the Latin American market. 
  

Middle East and Africa Gas Exchange Pulmonary Function Testing Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2024.

• This growth is driven by the kingdom’s healthcare transformation under Vision 2030, which prioritizes digital health, early diagnosis, and expanded access to specialized diagnostics. The Ministry of Health’s Ada’a Health Platform has significantly improved service delivery, reducing wait times and increasing efficiency across hospitals and clinics.
  
• The Saudi Food and Drug Authority (SFDA) enforces rigorous medical device regulations, ensuring safety and performance standards for pulmonary testing equipment. The country’s listing and registration system for medical devices supports transparency and quality control, enabling the introduction of advanced diagnostic technologies. WHO’s Global Atlas of Medical Devices confirms Saudi Arabia’s growing capacity in health technology management and device availability.
  
• Saudi Arabia’s healthcare infrastructure is rapidly modernizing, with increased investment in outpatient care, telemedicine, and public-private partnerships. The country’s leadership in regional health policy and its collaboration with global institutions like the CDC and WHO further strengthen its diagnostic capabilities.
  

Gas Exchange Pulmonary Function Testing Market Share

The global market is highly competitive, driven by continuous innovation, technological advancements, and strategic collaborations among leading medical device companies. Rising prevalence of chronic respiratory diseases, including COPD, asthma, and pulmonary fibrosis, coupled with growing patient awareness, is fueling demand for accurate, non-invasive diagnostic solutions.

Healthcare providers increasingly prioritize early detection, precise monitoring, and effective disease management, encouraging companies to invest in advanced pulmonary function testing systems such as spirometry platforms, gas diffusion analyzers, and cardiopulmonary exercise testing (CPET) devices. The shift toward home-based care and value-driven healthcare models further motivates market players to develop portable, patient-centric, and cost-efficient devices while expanding their footprint in emerging markets.

Key players in the market include Vyaire, Schiller, COSMED,  Vitalograph, and ECO MEDICS collectively accounting for 51.4% of the global market. These companies maintain their competitive advantage through extensive product portfolios, strong global distribution networks, and continuous advancements in pulmonary diagnostics. Their leadership is reinforced by strategic partnerships with hospitals, clinics, and diagnostic centers, enhancing device accessibility and adoption.

Smaller and niche players are also gaining traction by offering portable, user-friendly, and disease-specific solutions. As the market evolves, competition is expected to intensify, with both established leaders and emerging firms focusing on product innovation, digital health integration, and strategic alliances to expand market share and address growing clinical demands effectively.

Gas Exchange Pulmonary Function Testing Market Companies

Few of the prominent players operating in the gas exchange pulmonary function testing industry include:

• CHEST M.I.
• CORTEX
• COSMED
• ECO MEDICS
• Geratherm Respiratory
• Morgan Scientific
• MGC Diagnostics Holdings
• ndd Medical Technologies
• Schiller
• Sibelmed
• Vitalograph
• Vyaire
  
•  Vyaire

Vyaire leads the gas exchange pulmonary function testing market with a share of 31.6% in 2024. The company offers comprehensive pulmonary diagnostic solutions, including PFT, DLCO, and CPET systems, combining advanced technology, integrated software, and global service support to deliver accurate, reliable, and versatile respiratory assessments across hospitals, clinics, and diagnostic centers worldwide.

•  Schiller

Schiller provides precise, user-friendly pulmonary testing and CPET systems with versatile applications, strong clinical performance, and worldwide distribution, supported by strategic partnerships, enabling efficient respiratory diagnostics and improved patient care.

Gas Exchange Pulmonary Function Testing Industry News:

• In May 2023, Vitalograph, a leading company in respiratory diagnostics, expanded its product portfolio with the launch of the Vitalograph tremoflo C-100 Oscillometer at the ATS International Conference. The new device highlights the trend toward advanced, non-invasive testing methods such as oscillometry, providing detailed small airway function assessment without forced maneuvers, making it suitable for a broader range of patients, including children
  
• In January 2023, MGC Diagnostics Holdings, Inc. announced its acquisition by CAIRE Inc. This strategic move enables MGC to leverage CAIRE’s extensive global distribution network and manufacturing capabilities, improving patient access to its advanced cardiorespiratory diagnostic systems.
  
• In December 2022, ECO PHYSICS AG announced it had been granted certification under the new MDR. This accomplishment ensures compliance with stringent regulatory standards and strengthens ECO PHYSICS AG’s market position, supporting ongoing innovation and trust in its products.
  

The gas exchange pulmonary function testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By System Type

• Portable
• Stationary

Market, By Test Method

• Gas diffusion tests
• Cardiopulmonary exercise testing (CPET)

Market, By Application

• Chronic obstructive pulmonary disease
• Asthma
• Chronic shortness of breath
• Pulmonary fibrosis
• Other applications

Market, By End Use

• Hospitals & clinics
• Diagnostic centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE